119-HR-4348 Investigative Journalist Impact Analysis

Summary

What the bill does: H.R. 4348 reauthorizes CDC’s national strategy and the Regional Centers of Excellence in Vector‑Borne Diseases and renews cooperative agreements that support state and local health departments, shifting the authorization window to FY2026–2030. On May 21, 2026, the House Energy & Commerce Committee reported the bill by 48–0, positioning it for floor consideration. [2]U.S. House Committee on Energy & Commerce — E&C Health Subcommittee Markup Memo…

Economic Effects

Net effect likely modestly positive over the authorization window if funds sustain surveillance/training and reduce disease burden; effects will vary by state incidence and program uptake.

• Stabilized state capacity: Extending CDC cooperative agreements under 42 U.S.C. §300hh‑32 helps health departments maintain surveillance, lab capability, and response in high‑risk regions—reducing year‑to‑year funding shocks that impair workforce retention. [4]U.S. House - Office of the Law Revision Counsel — 42 U.S.C. §300hh-32 — Enhance…
• Workforce and R&D spillovers: CDC’s Centers of Excellence and Regional Training & Evaluation Centers train public‑health entomologists and evaluate prevention tools; reauthorization sustains this pipeline and applied know‑how that state programs depend on. [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)
• Potential cost offsets: Lyme disease drives substantial medical and productivity losses; a CDC prospective study estimates an annual aggregate cost of $345–$968 million (2016 USD) for diagnosed cases in high‑incidence areas. More effective prevention and earlier detection could trim a fraction of these costs. [6]CDC – Emerging Infectious Diseases — Economic Burden of Reported Lyme Disease i…
• Market signals: Steady federal demand for diagnostics, surveillance platforms, and training services supports small life‑science vendors and academic labs; effects are diffuse and not earmarked to specific firms in the bill text. (Analytical inference from program scope and existing CDC initiatives.) [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)
• Macroeconomic scale: Given authorization size typical of prior programs and the bounded scope (surveillance, training, applied research), broader GDP or employment effects are expected to be small but positive in affected sectors and regions. (Inference; no CBO score yet posted.) [7]Library of Congress — All Info - H.R.4348 (119th): To reauthorize the Kay Hagan…

Context for the metrics: CDC estimates ≈476,000 people are diagnosed and treated for Lyme annually (2010–2018); reported counts jumped to 62,551 in 2022 largely due to a surveillance definition change rather than a sudden risk surge, underscoring why prevention/surveillance investments should be evaluated against multiple indicators (claims, lab data, incidence). [8]CDC — CDC – Lyme Disease Surveillance and Data (476,000 estimate)

Social Effects

Impact concentrates in high‑incidence geographies and among populations with frequent tick exposure.

• High‑incidence corridors benefit most: Northeast, Mid‑Atlantic, Upper Midwest, and parts of Virginia/WV/Wisconsin show the greatest Lyme incidence and therefore the highest potential returns from stronger surveillance and prevention capacity. [9]CDC / MMWR — MMWR – Surveillance for Lyme Disease after Revised Case Definition…
• Workers at elevated risk: Outdoor and field‑based workers (forestry, utilities, construction, park services) face higher tick exposure; sustained guidance/training via public‑health channels reduces illness and lost productivity. [10]OSHA — OSHA – Tickborne Disease (worker risk and prevention)
• Alpha‑gal syndrome (AGS) awareness and diagnostics: Reauthorization supports vector surveillance and clinician education infrastructures that can improve AGS recognition in regions with expanding lone star tick populations; CDC estimates >110,000 suspected AGS cases (2010–2022), with as many as 450,000 people possibly affected. [11]CDC / MMWR — MMWR – Geographic Distribution of Suspected Alpha‑gal Syndrome (20…
• Equity lens: Rural residents and low‑income households—often with outdoor employment or limited access to specialty care—stand to benefit from standardized diagnostics and public‑health messaging coordinated through CDC programs. (Inference grounded in CDC program design and worker‑risk data.) [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)

Environmental Effects

Direct environmental impacts of H.R. 4348 are limited; secondary impacts arise through local tick‑control choices informed by federally supported programs.

• Program operations: Funding chiefly supports data systems, labs, training, and applied research—activities with a small physical footprint and minimal direct emissions. (Program‑scope inference.) [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)
• Integrated tick management (ITM): If jurisdictions scale ITM, some rely on acaricides (e.g., permethrin). EPA reviews indicate pyrethroids are effective but can pose ecological risks—especially to aquatic invertebrates—necessitating mitigation (buffer zones, drift/runoff controls). [13]U.S. EPA — EPA – Permethrin (RED Fact Sheet): toxicity and risk context
• Public guidance context: CDC emphasizes personal protection and targeted habitat management and cautions against relying on area spraying alone to reduce infection risk. [14]CDC — CDC – Preventing Tick Bites (personal protection; caution on spraying)
• Long‑run backdrop: Federal climate‑health assessments and EPA materials indicate warmer, longer seasons can expand tick activity and suitable habitat—reinforcing the value of surveillance and prevention quality rather than prompting indiscriminate chemical use. [15]U.S. EPA — EPA – Tick‑borne illness & school‑aged children (climate context)

Temporal Analysis

1. Near term (FY2026–FY2027): States leverage reauthorized funds to stabilize staffing, upgrade surveillance (including EHR‑based platforms), and refresh clinician/public guidance ahead of peak seasons. Expect measurable outputs (trained personnel, surveillance coverage) before large incidence shifts. [8]CDC — CDC – Lyme Disease Surveillance and Data (476,000 estimate)
2. Mid term (FY2028–FY2030): COEs/TECs mature evaluations of prevention tools; more consistent, multi‑source indicators (claims + lab + standardized reporting) improve signal quality, enabling targeted interventions in high‑incidence counties. [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)
3. Beyond 2030: Climate and land‑use trends could continue to expand risk zones; durable gains will depend on maintaining integrated approaches (habitat management, vaccination if available, community education) and on careful interpretation of surveillance artifacts. [15]U.S. EPA — EPA – Tick‑borne illness & school‑aged children (climate context)

Unintended Consequences

Risks and secondary effects to monitor through implementation.

• Data‑driven misperception: The 2022 case‑definition change increased reported Lyme counts by design in high‑incidence jurisdictions; without clear communication, stakeholders may misread trends as abrupt risk spikes or program failure/success. Mitigation: pair case counts with incidence and claims‑based estimates. [9]CDC / MMWR — MMWR – Surveillance for Lyme Disease after Revised Case Definition…
• Antibiotic stewardship: Expanded awareness may drive overtreatment if clinical standards aren’t emphasized. IDSA/AAN/ACR guidelines recommend against prolonged antibiotic therapy for patients with persistent, nonspecific symptoms after standard treatment absent objective evidence of active infection. [16]idsociety.org
• Environmental externalities: If jurisdictions default to broader acaricide use, aquatic and pollinator risks rise without EPA‑mandated mitigations. Program messaging should foreground non‑chemical controls and label‑compliant, targeted applications only. [17]U.S. EPA — EPA – Environmental Hazard & Labeling for Pyrethroid/Pyrethrin Produ…
• Stakeholder voice: With the Tick‑Borne Disease Working Group sunset and its consultation reference removed, HHS should use alternative engagement channels to capture patient/clinician input when setting priorities for surveillance and research. [18]HHS / Health.gov — HHS/Health.gov – Tick‑Borne Disease Working Group overview (…

Assessment

Overall stance: neutral. On balance, reauthorization is likely to deliver public‑health benefits—steadier surveillance, workforce development, and improved tool evaluation—at modest fiscal cost. Realizing those benefits depends on rigorous adherence to evidence‑based clinical guidance, transparent communication about surveillance artifacts, and environmentally responsible tick‑control practices. [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)

Sourcing

Primary sources used for this analysis.

• Legislative status and actions: House Committee repository vote record (48–0, May 21, 2026); Energy & Commerce Subcommittee markup memo (May 13, 2026). [1]U.S. House Committee on Energy & Commerce — E&C Full Committee Vote Record – H.…
• Program authorities: 42 U.S.C. §247b‑23 (COEs) and §300hh‑32 (state vector‑borne capacity). [3]LII / Cornell Law School — 42 U.S.C. §247b-23 — National strategy and regional…
• Program operations: CDC COEs, Regional Training & Evaluation Centers, DVBD overview. [5]CDC — CDC – Centers of Excellence in Vector-Borne Diseases (COEs)
• Burden and trends: CDC Lyme estimates and MMWR analysis of 2022 case‑definition effects; CDC case‑map resources. [8]CDC — CDC – Lyme Disease Surveillance and Data (476,000 estimate)
• Economic costs: CDC Emerging Infectious Diseases cost‑of‑illness study (2014–2016, published 2022). [6]CDC – Emerging Infectious Diseases — Economic Burden of Reported Lyme Disease i…
• Related conditions: CDC MMWR/newsroom materials on alpha‑gal syndrome. [11]CDC / MMWR — MMWR – Geographic Distribution of Suspected Alpha‑gal Syndrome (20…
• Environmental context: EPA pyrethroid risk/mitigation materials; CDC prevention guidance; climate‑health context from EPA/HHS. [13]U.S. EPA — EPA – Permethrin (RED Fact Sheet): toxicity and risk context
• Bill content note: Senate section‑by‑section shows removal of Tick‑Borne Disease Working Group consultation language during reauthorization. [12]U.S. Senate HELP Committee — Senate HELP section-by-section: Kay Hagan Tick Rea…